Quantum BioPharma Ltd. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
QNTM Nasdaq 2830 www.quantumbiopharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Quantum BioPharma Ltd.

Quantum BioPharma (QNTM) Advances Proprietary Therapy for MS Treatment - Jun 9th, 2026 12:51 pm
Quantum BioPharma (QNTM) Builds Diversified Pipeline Across Neurological and Wellness Markets - Jun 4th, 2026 1:30 pm
Quantum BioPharma (QNTM) Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire Podcast - Jun 2nd, 2026 1:50 pm
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd. - Jun 2nd, 2026 6:00 am
Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns - Jun 2nd, 2026 5:40 am
Quantum BioPharma Provides Corporate Update - Jun 1st, 2026 5:30 pm
Quantum BioPharma (QNTM) Reports Midpoint Enrollment Milestone in MS Imaging Study - May 19th, 2026 12:05 pm
Quantum BioPharma Reaches Halfway Point in Patient Enrollment in Imaging Study With MGH - May 19th, 2026 5:21 am
Quantum BioPharma Shares Climb as Multiple Sclerosis Imaging Study Advances (QNTM) - May 18th, 2026 8:37 am
Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital - May 18th, 2026 1:00 am
Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026 - May 7th, 2026 5:00 am
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant - Apr 22nd, 2026 7:16 am
Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied - Apr 2nd, 2026 6:30 am
Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis - Apr 1st, 2026 6:02 am
Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis - Mar 30th, 2026 5:50 am
Quantum Biopharma’s 2025 Audited Year End Financial Results Maintain ‘No Going Concern’ Status - Mar 27th, 2026 6:10 am
Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis - Mar 26th, 2026 6:00 am
Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd - Mar 23rd, 2026 6:24 am
Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering - Mar 20th, 2026 5:35 pm
Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS) - Dec 23rd, 2025 6:00 am